Ribbon Health vs Bristol Myers Squibb

Side-by-side comparison of AI visibility scores, market position, and capabilities

Bristol Myers Squibb leads in AI visibility (80 vs 35)
Ribbon Health logo

Ribbon Health

EmergingHealthTech

Provider Data API

Ribbon Health provides an API for accurate, real-time provider data — physician directories, insurance acceptance, and location details — helping health plans and apps build reliable care navigation.

AI VisibilityBeta
Overall Score
D35
Category Rank
#543 of 596
AI Consensus
82%
Trend
stable
Per Platform
ChatGPT
39
Perplexity
38
Gemini
40

About

Ribbon Health aggregates and continuously cleans provider data — physician names, specialties, practice locations, insurance plans accepted, and availability — and delivers it through an API that health technology companies, payers, and health systems use to build accurate provider directories and care navigation tools. The core problem Ribbon solves is that provider data decays rapidly as doctors change practices, update insurance contracts, and open or close locations, making directory accuracy a persistent challenge across the industry.

Full profile
Bristol Myers Squibb logo

Bristol Myers Squibb

LeaderHealthcare Tech

Enterprise

Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.

AI VisibilityBeta
Overall Score
A80
Category Rank
#18 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
78
Gemini
80

About

Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).

Full profile

AI Visibility Head-to-Head

35
Overall Score
80
#543
Category Rank
#18
82
AI Consensus
83
stable
Trend
stable
39
ChatGPT
78
38
Perplexity
78
40
Gemini
80
40
Claude
84
33
Grok
77

Key Details

Category
Provider Data API
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Ribbon Health
Provider Data API

Integrations

Only Bristol Myers Squibb
Bristol Myers Squibb is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.